Book a call

← Recognition

Our story

ElohimElohaElohaX

Named for the source of life, ElohaX began as a University of Hong Kong team asking a question no AI drug tool was built for, what actually causes Alzheimer's, and turned the answer into DeepDrug, which repurposes approved medicines against those root causes and has since seen 11 of its top 20 picks backed by independent studies.

University of Hong Kong spin-offWith Cambridge scientists.
4 NAM awardsUS National Academy of Medicine, Healthy Longevity Catalyst Awards, 2021 to 2024.
One of 30 semifinalistsSelected from 1,600 applications in the NAM Healthy Longevity competition, 2026.
11 of 20 validatedTop picks later backed by other scientists' studies.

Source: Li, …, Lam, DeepDrug, Scientific Reports 2025

DeepDrug · Causal AI for Alzheimer's drug repurposing

Know which repurposed drugs to test next, and why.

Send us up to 50 repurposed drugs or combinations. DeepDrug's causal AI ranks them against the root causes that drive Alzheimer's and returns a shortlist with the target genes, pathways, evidence and safety behind every score, in one week.

Book a 30-minute conversation

11 of 20 of our top picks were later backed by other scientists' studies.

How DeepDrug thinks Approved drugs act on root causes, and root causes drive Alzheimer's. Tofacitinib acts on inflammation, niraparib on energy failure, empagliflozin on sugar metabolism. APPROVED DRUGS ROOT CAUSES DISEASE Tofacitinib Niraparib Empagliflozin Inflammation Energy failure Sugar metabolism Alzheimer's act on drive
DeepDrug finds the root causes behind Alzheimer's, then matches approved drugs to repurpose against them. Shown: 3 of the 5 drugs in our lead combination.
How it works

Send us repurposed drugs. Get a ranked list. Repeat.

1

Send your repurposed drugs

Up to 50 repurposed drugs or combinations, and your question.

  • Drug Aapproved drug
  • Drug Bapproved drug
  • Drug C + Dcombination
  • + up to 50
2

DeepDrug ranks them

Graph AI and causal AI score each drug against Alzheimer's root causes.

  • Drug B0.88
  • Drug C + D0.81
  • Drug A0.52
  • Drug E0.23
3

You get the top list

A ranked shortlist, with the reasons.

  • Ranked shortlist
  • Root cause, mechanism and safety per drug
  • Best combination from your list
Results in 1 week
Repeat with your next batch. Tell us what your lab found. DeepDrug learns from it and ranks your next list.
Under the hood

What's inside the ranking, so you can check it.

Most AI in drug discovery finds patterns. DeepDrug is causal AI: it traces which genes and pathways drive Alzheimer's, then asks which approved drugs hit them. Each step is described in our published papers, and every result traces back through it.

  1. 1Alzheimer's biology graphGenes, pathways and drugs linked in one signed, directed graph: each edge records which way the effect runs and whether it activates or inhibits.
  2. 2Expert weightingNeuroscience and clinical experts weight the graph toward the immune, aging and genetic pathways tied to Alzheimer's. DeepDrug2 adds germline genes from recent genome-wide studies.
  3. 3Graph neural networkLearns how each drug relates to each disease gene. On link-prediction tests it scores 0.98 AUC and 0.98 average precision.
  4. 4Drug and combination scoringRanks each drug on how strongly it hits the disease-driving genes, then searches combinations (3,003 five-drug sets in our own run) for the best joint coverage.
  5. 5Checked against the real worldTop picks are compared with independent trials, animal studies and health records we had no hand in.

What you can inspect for every drug

  • The root cause it hits
  • The target genes and pathways behind its score
  • Direction of effect: does it push the pathway the right way?
  • Published evidence for, and against
  • Known safety profile as an approved drug

How we've tested it

11 of 20top DeepDrug picks later backed by independent studies: 4 human trials, 2 health-record studies, 5 animal models.
3 of 15single drugs among 15 testable DeepDrug2 picks, each linked to significantly lower Alzheimer's odds in UK Biobank records of 502,163 people, adjusted for age, sex, ethnicity and comorbidities.

Methods: Li et al., DeepDrug, Scientific Reports 2025; Li, Han, Lam & Downey, DeepDrug2, medRxiv 2025 (preprint).

Work with us

Two ways to work with us.

For your research team

Use our causal AI

Run your own repurposed drugs through DeepDrug, for one project or all year round.

How you payA fee per project, or a yearly fee
For your partnering and clinical teams

License our five-drug combination

Start from the lead combination of five repurposed drugs we've already found, or develop it with us.

How you payAn upfront fee, then a share of success
Next step

Bring us your next list of repurposed drugs.

Start with a pilot: send one batch of up to 50 repurposed drugs, and get your ranked results, with reasons, in 1 week. It begins with a 30-minute call with the founders.

Mrs. Ingrid KwokChair of the Advisory Board

Guides ElohaX's strategy and governance, keeping our Alzheimer's work built for long-term social impact.

Prof. Victor O.K. LiCo-Founder & CEO
vli@eee.hku.hk
Prof. Jacqueline C.K. LamCo-Founder & COO
jcklam@eee.hku.hk

A familiar medicine, so a familiar face stays familiar.